its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest ...

today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. "Heading into 2025, Ventyx has established itself as the leader in the field ...

Dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease; Program update expected in the first half of 2025 New England Journal of Medicine publication of Phase 1 study of RP-A501 ...

Financial Highlights Cash position: As of December 31, 2024, the Company held cash, cash equivalents and investment securities of $367.5 million, compared to $617.9 million as of December 31, 2023.

Avidity reported its 2025 outlook, including upcoming clinical and regulatory highlights, and recent organization appointments to execute on the full range of strategic initiatives and growth ...

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...

Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent ...

today reported financial results for the fourth quarter and full year 2024 and recent business highlights. “Our most recent clinical data for DYNE-101 from the ACHIEVE trial in DM1 patients ...

today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2024. “We are off to an excellent start in 2025 with renewed focus and strong ...

Recent Company Developments and Updates Pursuing Accelerated Approval of AMT-130 for the treatment of Huntington’s disease In May 2024, the FDA granted Regenerative Medicine Advanced Therapy ...

today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We made tremendous progress in 2024 which was capped off by the ...

today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "Our most recent clinical data for DYNE-101 from the ACHIEVE trial in DM1 patients showed ...